Grant: Doctoral Research Award - Priority Announcement: HIV/AIDS - Basic Science
University of Toronto
$105,000.00
Structural and functional studies at the HIV-1 viral infectivity factor-APOBEC3 axis
EF 2014-15
Résumé
Once HIV enters its target cell in the immune system, it releases its genetic material. The virus then incorporates its genetic codes into the host's genome as it synthesizes a DNA copy of its genetic material. To restrict this deleterious incorporation, the infected cells activate restrictive proteins that target the viral genome, thereby inactivating the viral pathogenesis. However, fully replicating HIV encodes for an accessory protein which binds to these cellular restrictive proteins, targets them for degradation, and therefore neutralizes their antiviral effects.
In our research, we propose to study the structure and function of this accessory protein, which is currently believed by many researchers to be the most attractive target for the development of new anti-HIV drugs.
The structural studies of several international groups on a complex of this viral protein and the restrictive proteins of our immune system had been hindered until recently when I identified the experimental conditions to prepare high levels of this protein complex for biophysical, structural and drug discovery purposes. Given my preliminary results, our lab is now in a strong position to study and fully describe the atomic-resolution structure of this protein. Our research will provide a 'blueprint' for future design of a new class of HIV-1 therapeutics that can inactivate highly mutagenic HIV.
Programme
Doctoral Research Award - Priority Announcement: HIV/AIDS - Basic Science
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
317845
Name
Azimi Farshad
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association for HIV Research (Ottawa)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Structural and functional studies at the HIV-1 viral infectivity factor-APOBEC3 axis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - Priority Announcement: HIV/AIDS - Basic Science
Keyworddelim
Aids (Acquired Immunodeficiency Syndrome); Biophysical Structure Determination Techniques; Hiv (Human Immunodeficiency Virus); Hiv Viral Infectivity Factor (Vif); Human Antiretroviral Apobec3 Enzymes; Molecular/Cellular Immunology; Nmr Spectroscopy; Protein-Protein Interactions; Viral And Human Protein Biochemistry; X-Ray Crystallography
Abstract
Once HIV enters its target cell in the immune system, it releases its genetic material. The virus then incorporates its genetic codes into the host's genome as it synthesizes a DNA copy of its genetic material. To restrict this deleterious incorporation, the infected cells activate restrictive proteins that target the viral genome, thereby inactivating the viral pathogenesis. However, fully replicating HIV encodes for an accessory protein which binds to these cellular restrictive proteins, targets them for degradation, and therefore neutralizes their antiviral effects.
In our research, we propose to study the structure and function of this accessory protein, which is currently believed by many researchers to be the most attractive target for the development of new anti-HIV drugs.
The structural studies of several international groups on a complex of this viral protein and the restrictive proteins of our immune system had been hindered until recently when I identified the experimental conditions to prepare high levels of this protein complex for biophysical, structural and drug discovery purposes. Given my preliminary results, our lab is now in a strong position to study and fully describe the atomic-resolution structure of this protein. Our research will provide a 'blueprint' for future design of a new class of HIV-1 therapeutics that can inactivate highly mutagenic HIV.
Competitiondate
201410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Azimi, Farshad
Approvedterm
3 ans 0 mois
Cihrcontribution2
HIV/AIDS~ $105,000~ $0~